{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:40:39Z","timestamp":1791819639620,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RO 3577\/3\\u20132 ( KFO 337"],"award-info":[{"award-number":["RO 3577\/3\\u20132 ( KFO 337"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SCHA 422\/17\\u20131"],"award-info":[{"award-number":["SCHA 422\/17\\u20131"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HO 6389\/2\\u20131"],"award-info":[{"award-number":["HO 6389\/2\\u20131"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KFO 337"],"award-info":[{"award-number":["KFO 337"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002714","name":"Albert-Ludwigs-Universit\u00e4t Freiburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002714","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021729","name":"Medizinische Fakult\u00e4t der Albert-Ludwigs-Universit\u00e4t Freiburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021729","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ejca.2021.04.032","type":"journal-article","created":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T05:46:36Z","timestamp":1622871996000},"page":"139-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases"],"prefix":"10.1016","volume":"152","author":[{"given":"Anne","family":"Zaremba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4704-5778","authenticated-orcid":false,"given":"Manuel","family":"Philip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7575-6230","authenticated-orcid":false,"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Glutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeno","family":"Fiocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Loquai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7850-3199","authenticated-orcid":false,"given":"David","family":"Rafei-Shamsabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gutzmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Utikal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Haferkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6232-5132","authenticated-orcid":false,"given":"Lydia","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina C.","family":"K\u00e4hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1195-2106","authenticated-orcid":false,"given":"Carsten","family":"Weishaupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5244-9286","authenticated-orcid":false,"given":"Alvaro","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Martin","family":"Thoms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabea","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pf\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Roesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Ugurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3680-3521","authenticated-orcid":false,"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Stadtler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Sucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Kiecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Heinzerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedegund","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4044-9094","authenticated-orcid":false,"given":"Frank","family":"Meiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Schlaak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8859-4103","authenticated-orcid":false,"given":"Bastian","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2902-0377","authenticated-orcid":false,"given":"Susanne","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3524-7858","authenticated-orcid":false,"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8279-9239","authenticated-orcid":false,"given":"Elisabeth","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2021.04.032_bib1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1245\/s10434-014-4100-0","article-title":"In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy","volume":"22","author":"Read","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2021.04.032_bib2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1586\/17469872.3.5.569","article-title":"Current concepts of metastasis in melanoma","volume":"3","author":"Zbytek","year":"2008","journal-title":"Expet Rev Dermatol"},{"issue":"4","key":"10.1016\/j.ejca.2021.04.032_bib3","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1445-2197.2002.02376.x","article-title":"Melanoma: margins for error - another view","volume":"72","author":"McCarthy","year":"2002","journal-title":"ANZ J Surg"},{"issue":"8","key":"10.1016\/j.ejca.2021.04.032_bib4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1245\/ASO.2005.05.025","article-title":"Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy","volume":"12","author":"Pawlik","year":"2005","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2021.04.032_bib5","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2021.04.032_bib6","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2021.04.032_bib7","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ejca.2021.04.032_bib8","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"Jama"},{"issue":"4","key":"10.1016\/j.ejca.2021.04.032_bib9","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.04.032_bib10","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.intimp.2016.09.030","article-title":"Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy","volume":"40","author":"Felix","year":"2016","journal-title":"Int Immunopharm"},{"key":"10.1016\/j.ejca.2021.04.032_bib11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2017.05.033","article-title":"Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials","volume":"82","author":"Schadendorf","year":"2017","journal-title":"Eur J Canc"},{"issue":"11","key":"10.1016\/j.ejca.2021.04.032_bib12","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB\u2013C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.04.032_bib13","series-title":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe,AWMF): diagnostik, Therapie und Nachsorge des Melanoms, Langversion 3.3","year":"2020"},{"key":"10.1016\/j.ejca.2021.04.032_bib14","series-title":"RCT. R: a language and environment for statisticalcomputing","year":"2020"},{"issue":"22","key":"10.1016\/j.ejca.2021.04.032_bib15","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1200\/JCO.19.03034","article-title":"Prognosis of patients with stage III melanoma according to American Joint committee on cancer version 8: a reassessment on the basis of 3 independent stage III melanoma cohorts","volume":"38","author":"Garbe","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2021.04.032_bib16","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA","volume":"67","author":"Gershenwald","year":"2017","journal-title":"A Cancer Journal for Clinicians"},{"issue":"12","key":"10.1016\/j.ejca.2021.04.032_bib17","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1016\/j.jid.2017.07.006","article-title":"Serial or parallel metastasis of cutaneous melanoma? A study of the German central malignant melanoma registry","volume":"137","author":"Gassenmaier","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"35","key":"10.1016\/j.ejca.2021.04.032_bib18","doi-asserted-by":"crossref","first-page":"10995","DOI":"10.1073\/pnas.1508074112","article-title":"Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination","volume":"112","author":"Sanborn","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2021.04.032_bib19","doi-asserted-by":"crossref","first-page":"10070","DOI":"10.1200\/JCO.2020.38.15_suppl.10070","article-title":"Checkpoint inhibitor treatment in patients with isolated in-transit melanoma metastases","volume":"38","author":"Storey","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2021.04.032_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000440","article-title":"Efficacy of immune checkpoint inhibitors for in-transit melanoma","volume":"8","author":"Nan Tie","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2021.04.032_bib21","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.ejca.2021.04.032_bib22","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41416-020-0994-4","article-title":"Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives","volume":"123","author":"Middleton","year":"2020","journal-title":"Br J Canc"},{"issue":"6","key":"10.1016\/j.ejca.2021.04.032_bib23","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/ans.14921","article-title":"Management of in-transit melanoma metastases: a review","volume":"89","author":"Nan Tie","year":"2019","journal-title":"ANZ J Surg"},{"issue":"6","key":"10.1016\/j.ejca.2021.04.032_bib24","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/01.sla.0000146147.89667.ed","article-title":"One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases","volume":"240","author":"Gr\u00fcnhagen","year":"2004","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.ejca.2021.04.032_bib25","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1634\/theoncologist.2009-0325","article-title":"Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety","volume":"15","author":"Moreno-Ramirez","year":"2010","journal-title":"Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.04.032_bib26","doi-asserted-by":"crossref","first-page":"367","DOI":"10.6004\/jnccn.2019.0018","article-title":"Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in Oncology","volume":"17","author":"Coit","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"17","key":"10.1016\/j.ejca.2021.04.032_bib27","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1002\/cncr.25156","article-title":"High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma","volume":"116","author":"Weide","year":"2010","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2021.04.032_bib28","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/jso.23702","article-title":"Treatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review","volume":"110","author":"Byers","year":"2014","journal-title":"J Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2021.04.032_bib29","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/jso.26121","article-title":"Lesional therapies for in-transit melanoma","volume":"122","author":"Nadler","year":"2020","journal-title":"J Surg Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2021.04.032_bib30","doi-asserted-by":"crossref","first-page":"9568","DOI":"10.1200\/JCO.2016.34.15_suppl.9568","article-title":"Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma","volume":"34","author":"Long","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2021.04.032_bib31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III\u2013IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2021.04.032_bib32","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s12325-020-01590-w","article-title":"A retrospective chart review study of real-world use of talimogene laherparepvec in unresectable stage IIIB\u2013IVM1a melanoma in four European countries","volume":"38","author":"van Akkooi","year":"2021","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.ejca.2021.04.032_bib33","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/jso.25601","article-title":"Correlates of response and outcomes with talimogene laherperpvec","volume":"120","author":"Zhou","year":"2019","journal-title":"J Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.04.032_bib34","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jamcollsurg.2018.12.027","article-title":"Real-world outcomes of talimogene laherparepvec therapy: a multi-institutional experience","volume":"228","author":"Louie","year":"2019","journal-title":"J Am Coll Surg"},{"issue":"Supplement_5","key":"10.1016\/j.ejca.2021.04.032_bib35","article-title":"LBA70Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis of a randomized, open-label, phase II trial","volume":"30","author":"Chesney","year":"2019","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921002781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921002781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:31:38Z","timestamp":1777599098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921002781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":35,"alternative-id":["S0959804921002781"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.04.032","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.04.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}